MSA Safety (MSA) Upgraded to Buy: Here's What You Should Know
MSA Safety (MSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare neurodegenerative disease with no approved disease-modifying therapies. MSA is a rapidly progressive disorder that affects autonomic functions such as blood pressure and bladder control, as well as motor control, leading to severe disability and shortened life expectancy.
MSA Safety: Industrial PPE Up, Fire Service And Detection Mixed
MSA Safety delivered Q2 2026 results with revenue of $503M, beating consensus by $7M and adjusted EPS up 24% year-over-year. Adjusted operating margin expanded 270 bps to 24.1%, and free cash flow reached $83M, reflecting strong productivity and pricing actions. Detection segment revenue rose 4%, driven by the M&C TechGroup acquisition and robust Americas organic growth, offset by international weakness.
MSA Safety Incorporated (MSA) Q2 2026 Earnings Call Transcript
MSA Safety Incorporated (MSA) Q2 2026 Earnings Call Transcript
MSA Safety Incorporporated Q2 Earnings Call Highlights
MSA Safety Incorporporated NYSE: MSA reported higher second-quarter sales, earnings and cash flow, while maintaining its outlook for mid-single-digit organic growth in 2026. The company also said it completed its acquisition of Autronica Fire and Security in early July.
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal foralumab, with PET scans showing reductions in brain inflammation following treatment. The company said quantitative analysis of PET imaging demonstrated reductions in inflammatory activity in brain regions commonly affected by MSA, including the basal ganglia and cerebellar white matter.
MSA Safety (MSA) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for MSA Safety (MSA) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MSA Safety (MSA) Surpasses Q2 Earnings and Revenue Estimates
MSA Safety (MSA) came out with quarterly earnings of $2.4 per share, beating the Zacks Consensus Estimate of $2.14 per share. This compares to earnings of $1.93 per share a year ago.
MSA Safety: A Recipe For Growth
MSA Safety is a Dividend King with a 56-year streak, robust cash flow, and a disciplined growth strategy via innovation and bolt-on M&A. Recent Q1 2026 results showed 10% revenue growth and 18% non-GAAP EPS growth, beating consensus and supporting a positive outlook. MSA trades at ~18x 2026E EPS, below its 5-year average, with a fair value estimate of $177.60 versus a current price of ~$159.89, indicating undervaluation.
MSA Safety Incorporated (MSA) Presents at 2026 Baird Global Consumer, Technology & Services Conference Transcript
MSA Safety Incorporated (MSA) Presents at 2026 Baird Global Consumer, Technology & Services Conference Transcript
MSA Safety Incorporated (MSA) Presents at 46th Annual William Blair Growth Stock Conference Transcript
MSA Safety Incorporated (MSA) Presents at 46th Annual William Blair Growth Stock Conference Transcript
MSA Safety Incorporporated Q1 Earnings Call Highlights
MSA Safety Incorporporated NYSE: MSA reported a stronger first quarter of fiscal 2026, with management citing resilient demand in the Americas, improved margins and continued execution of its Accelerate strategy, while also noting pressure in Europe and the Middle East.
